Showing 2191-2200 of 2314 results for "".
- Ribomic Announces Positive Topline Results from the Phase 1/2a Clinical Trial of RBM-007 (SUSHI Study) in Subjects with Wet AMDhttps://modernod.com/news/ribomic-announces-positive-topline-results-from-the-phase-1-2a-clinical-trial-of-rbm-007-sushi-study-in-subjects-with-wet-amd/2476656/Ribomic announced positive topline results from its SUSHI study, a phase 1/2a single ascending dose clinical study of RBM-007, anti-FGF2 aptamer, in nine subjects with wet age-related macular degeneration (AMD). The SUSHI study achiev
- Amarantus Announces Issuance of US Patent Covering MANF Treatment of Wolfram’s Syndrome, Retinitis Pigmentosa, and Glaucomahttps://modernod.com/news/amarantus-announces-issuance-of-us-patent-covering-manf-treatment-of-wolframs-syndrome-retinitis-pigmentosa-and-glaucoma/2476653/Amarantus Bioscience Holdings announced that subsidiary MANF Therapeutics was issued US Patent No. 10,195,251 entitled “Methods of Treatment for Retinal Diseases Using MANF and CDNF” that covers the use of mesencephalic astrocyte-derived neurotrophic factor (MANF) or cerebral dopamine
- Aerpio Initiates Phase 1b Clinical Trial of Topical Ocular Formulation of AKB-9778 for Primary Open Angle Glaucomahttps://modernod.com/news/aerpio-initiates-phase-1b-clinical-trial-of-topical-ocular-formulation-of-akb-9778-for-primary-open-angle-glaucoma/2476645/Aerpio Pharmaceuticals dosing of the first subject in a phase 1b trial of a topical ocular formulation of AKB-9778 in development for treatment of primary open angle glaucoma (POAG). The phase 1 study is a double-masked, multiple-ascending dose trial and will enroll four cohorts of 12 subj
- Roche’s Purchase of Spark Therapeutics Faces Further Delay Amid Scrutiny From US, UK Regulatorshttps://modernod.com/news/roches-purchase-of-spark-therapeutics-faces-further-delay-amid-scrutiny-from-us-uk-regulators/2476640/The US Federal Trade Commission requested additional information and documentary material from Roche and Spark Therapeutics in connection with its review of the companies’ pending deal, the drugmakers reported Monday. Roche noted that as a result, its $4.3-billion offer to acquire Spark has
- Pioneering Ophthalmologist Patricia Bath, MD, Dies at 76https://modernod.com/news/pioneering-ophthalmologist-patricia-bath-md-dies-at-76/2476632/Patricia E. Bath, MD, an ophthalmologist who took a special interest in combating preventable blindness in underserved populations and became the first black female doctor to patent a medical invention, a laser device for treating cataracts, died at the age of 76, acc
- Eyenovia Enrolls First Patient in Phase 3 CHAPERONE Study for Progressive Myopiahttps://modernod.com/news/eyenovia-enrolls-first-patient-in-phase-3-chaperone-study-for-progressive-myopia/2476629/Eyenovia announced that it has initiated its MicroPine phase 3 program with the first patient enrolled in its CHAPERONE study, a US-based, multicenter, randomized, double-masked trial that will enroll more than 400 children between 3-12 years of age. CHAPERO
- FDA Wins Case Against Florida Stem Cell Clinic that Harmed three Women’s Visionhttps://modernod.com/news/fda-wins-case-against-florida-stem-cell-clinic-that-harmed-three-womens-vision/2476631/The FDA has won a federal judge’s backing for its efforts to crack down on the rapidly growing stem cell industry that promises all kinds of unproven treatments for serious diseases, according to an NBC News
- Study: 3D Printed Artificial Corneas Similar to Human Oneshttps://modernod.com/news/study-3d-printed-artificial-corneas-similar-to-human-ones/2476615/When a person has a severely damaged cornea, a corneal transplant is required. However, there are 2,000 patients waiting for the cornea donation in the country as of 2018, and they wait for 6 or more years on average for the donation. For this reason, many scientists have put their efforts in dev
- Alimera Sciences Announces Launch of Direct-to-Patient Marketing Campaign for Iluvienhttps://modernod.com/news/alimera-sciences-announces-launch-of-direct-to-patient-marketing-campaign-for-iluvien/2476603/Alimera Sciences announced the launch of a direct-to-patient (DTP) marketing campaign intended to raise awareness and educate patients diagnosed with diabetic macular edema (DME) and their caregivers about the therapeutic and dosing benefits of Iluvien. The campaign will be supported by the websi
- Evaluation of a Remote Diagnosis Imaging Model vs Dilated Eye Examination in Referable Macular Degenerationhttps://modernod.com/news/evaluation-of-a-remote-diagnosis-imaging-model-vs-dilated-eye-examination-in-referable-macular-degeneration/2476596/Researchers examined if the identification of referable macular degeneration could be done using the remote diagnosis imaging model as a clinical screening tool. They conducted a nonrandomized study of 159 patients in facilities with high rates of diabetic retinopathy and age-related macular dege